<unk>  (research code MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound, first isolated from Syzygium claviflorum, a Chinese herb. It is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition. It is not currently U.S. Food and Drug Administration (FDA) approved. It was originally developed by the pharmaceutical company Panacos and reached Phase IIb clinical trials. Myriad Genetics announced on January 21, 2009 the acquisition of all rights to<unk>  for $7M USD. On June 8, 2010 Myriad Genetics announced that it was halting the development of maturation inhibitors, including<unk> , to focus more on their oncology portfolio.
Bevirimat
Remdesivir
Tecovirimat
Viaspan
Odalasvir
Seviteronel
Telotristat ethyl
Ritonavir